Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of HMGCoA reductase inhibitor in preparation of medicine used for treating xerophthalmia

A reductase inhibitor and dry eye technology, applied in the field of medicine, can solve the problems of ineffective treatment for the cause and large local side effects, and achieve the effects of avoiding first-pass effect, fast onset and good fat solubility.

Inactive Publication Date: 2013-04-03
闫莹
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Aiming at the shortcomings of current dry eye and ocular surface immune-related disease treatment drugs that have large local side effects or mainly rely on the systemic pharmacological effects of the drug and cannot effectively treat the cause, the invention provides a dry eye drug with good therapeutic effect and low toxic and side effects. Eye Treatment Drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of HMGCoA reductase inhibitor in preparation of medicine used for treating xerophthalmia
  • Application of HMGCoA reductase inhibitor in preparation of medicine used for treating xerophthalmia
  • Application of HMGCoA reductase inhibitor in preparation of medicine used for treating xerophthalmia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 contains the eye drops of HMGCoA reductase inhibitor

[0022] Eye drops are prepared according to methods known in the art, containing the following ingredients;

[0023] Simvastatin Eye Drops

[0024] Simvastatin 50mg

[0025] Hydroxypropyl methylcellulose 0.3g

[0026] Artificial tears 100ml

Embodiment 2

[0027] Embodiment 2 contains the eye drops of HMGCoA reductase inhibitor

[0028] Eye drops are prepared according to methods known in the art, containing the following ingredients;

[0029] Pravastatin Eye Drops

[0030] Pravastatin 10mg

[0031] Hydroxypropyl methylcellulose 0.3g

[0032] Artificial tears 100ml

Embodiment 3

[0033] Embodiment 3 contains the eye drop of HMGCoA reductase inhibitor

[0034] Eye drops are prepared according to methods known in the art, containing the following ingredients;

[0035] lovastatin eye drops

[0036] Lovastatin 5mg

[0037] Hydroxypropyl methylcellulose 0.3g

[0038] Artificial tears 100ml

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of an HMGCoA reductase inhibitor in preparation of a medicine used for treating xerophthalmia and belongs to the field of medicines. The inventor finds that a frequently-used lipid regulation medicine, the HMGCoA reductase inhibitor, can obviously prolong SIT time and BUT time and obviously reduce an FLS score when being used for treating the xerophthalmia, and the HMGCoA reductase inhibitor is better than ciclosporin or artificial tears in the aspect of improving the indexes, wherein simvastatin and lovastatin have the best treatment effect. The HMGCoA reductase inhibitor also can be prepared into oral preparation used for treatment or adjuvant therapy of the xerophthalmia. The HMGCoA reductase inhibitor has a definite curative effect and less toxic and side effects, compliance of a patient is high, and clinical ophthalmic drugs are further enriched.

Description

technical field [0001] The invention relates to a new application of a known drug, in particular to the application of an HMGCoA reductase inhibitor in the preparation of a drug for treating dry eye syndrome, and belongs to the field of medicine. Background technique [0002] Dry eye syndrome is a kind of disease caused by tear film instability or ocular surface tissue damage caused by abnormal tear quantity or quality, which leads to ocular discomfort symptoms. It is a common ophthalmological disease. Common symptoms include dry eyes , easy fatigue, drowsiness, itching, foreign body sensation, burning sensation, tight and heavy eyelids, sticky secretions, fear of wind, photophobia, sensitivity to external stimuli, temporary blurred vision; sometimes the eyes are too dry, Insufficiency of basic tears stimulates reflex tear secretion and causes frequent tearing symptoms; in severe cases, the eyes will be red, swollen, congested, keratinized, corneal epithelium is broken and f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/366A61K31/22A61P27/02
Inventor 闫莹
Owner 闫莹
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com